Doctor’s Diary, Entry 4: The Detective and the Woman Who Said Nothing
A man convinced his wife's hormones are the problem. A woman whose husband answers every question for her. Two composite vignettes from one fictional clinic afternoon.
All
Doctor’s Diary, Entry 3: The Bride and the Boy Who Almost Wasn’t
A bride who needs answers before Saturday. A sixteen-year-old boy with mild numbers and a mother carrying more hope than he is. Two composite vignettes from one fictional clinic morning.
Doctor’s Diary, Entry 2: The Calculator and the Quiet Man
A Wednesday morning. A man with a calculator and an invented ratio. A man who has been quietly afraid for eleven years. Two composite vignettes from one fictional clinic.
Doctor’s Diary, Entry 1: The First Patient
A woman who arrived with a folder convinced her thyroid was destroyed. A man who did not know he had diabetes. Two patients on one fictional Tuesday morning. Composite vignettes.
SOS Study: Bariatric Surgery Reduces Long-Term All-Cause Mortality by 29% in Severe Obesity
The Swedish Obese Subjects (SOS) study demonstrated that bariatric surgery is associated with a 29% reduction in adjusted all-cause mortality compared with conventional obesity treatment over an average 10.9 years of follow-up, with reductions in both cardiovascular and cancer deaths, providing the first prospective controlled evidence for the long-term survival benefit of surgical weight loss.
Look AHEAD: Intensive Lifestyle Intervention Does Not Reduce Cardiovascular Events in Obese Type 2 Diabetes
The Look AHEAD trial demonstrated that intensive lifestyle intervention targeting weight loss in overweight or obese adults with type 2 diabetes did not reduce cardiovascular events over 9.6 years despite clear differences in weight, fitness, and glycaemic control, establishing a critical negative result that informed the rationale for pharmacological obesity treatment with greater weight loss efficacy.
SCALE: Liraglutide 3.0 mg for Obesity — The Trial That Opened the GLP-1 Weight Management Era
The SCALE trial established liraglutide 3.0 mg as the first GLP-1 receptor agonist approved for chronic weight management, demonstrating a mean weight reduction of 8.0% versus 2.6% with placebo and a 79% reduction in progression from prediabetes to type 2 diabetes in a 160-week extension analysis, setting the clinical and regulatory template for GLP-1 receptor agonist obesity pharmacotherapy.
SELECT: Semaglutide 2.4 mg Reduces Cardiovascular Events by 20% in Obese Non-Diabetic Patients with CVD
The SELECT trial demonstrated that semaglutide 2.4 mg reduces 3-point MACE by 20% in overweight or obese adults with pre-existing cardiovascular disease and no diabetes, becoming the first obesity pharmacotherapy trial to demonstrate a hard cardiovascular endpoint benefit and establishing GLP-1 receptor agonism as a cardiovascular intervention in non-diabetic obesity.
SURMOUNT-1: Tirzepatide Achieves up to 20.9% Weight Loss in Obesity — Entering Surgical Territory
SURMOUNT-1 demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent mean weight reductions of 15.0–20.9% in adults with obesity without type 2 diabetes, with 57% of participants at the 15 mg dose losing 20% or more of body weight, setting a new pharmacological efficacy benchmark comparable in magnitude to bariatric surgery outcomes.
STEP 1: Semaglutide 2.4 mg Produces Unprecedented 14.9% Weight Loss in Obesity Without Diabetes
STEP 1 demonstrated that once-weekly semaglutide 2.4 mg produced a mean weight reduction of 14.9% compared with 2.4% with placebo in adults with obesity without type 2 diabetes, with a third of participants losing more than 20% of body weight, setting a new benchmark for pharmacological weight management and preceding the cardiovascular outcomes evidence from SELECT.